There are 3397 resources available
Q&A and Discussion
Presenter: All Speakers
Session: Current issues in primary prevention and screening to block the onset or development of cancer
Resources:
Slides
Webcast
ctDNA clearance: Surrogacy for cure and organ-sparing approaches
Presenter: Jeanne Tie
Session: Circulating tumour DNA: A perfect fit?
Resources:
Slides
Webcast
Conclusions
Presenter: Teresa Amaral
Session: YO Fellowship Session: Fellowships in Europe: Educational opportunities for young oncologists
Resources:
Slides
Webcast
Discussion
Presenter: All Speakers
Session: Circulating tumour DNA: A perfect fit?
Resources:
Slides
Webcast
Awards: Presentation of the 2023 Fellows and Best Exam
Presenter: Nadia Saoudi Gonzalez
Session: YO Fellowship Session: Fellowships in Europe: Educational opportunities for young oncologists
Resources:
Slides
Webcast
1321MO - Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2 (ERBB2)-mutant (HER2m) metastatic non–small cell lung cancer (NSCLC) with and without brain metastases (BMs): Pooled analyses from DESTINY-Lung01 and DESTINY-Lung02
Presenter: David Planchard
Session: Mini oral session 2 - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
654O - Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with solid tumors harboring specific HER2-activating mutations (HER2m): Primary results from the international phase II DESTINY-PanTumor01 (DPT-01) study
Presenter: Bob Li
Session: Proffered Paper session - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
1209MO - Computer-aided HCC lesion detection based on deep learning and CT images
Presenter: Oliver Lucidarme
Session: Mini oral session - Basic science & translational research
Resources:
Abstract
Slides
Webcast
1182O - Temozolomide treatment induces an MMR-dependent hypermutator phenotype in well differentiated pancreatic neuroendocrine tumors
Presenter: Louis de Mestier du Bourg
Session: Proffered Paper session - NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
1772MO - Pembrolizumab (pembro) plus enzalutamide (enza) and androgen deprivation therapy (ADT) for patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): Randomized double-blind phase III KEYNOTE-991 study
Presenter: Christian Gratzke
Session: Mini oral session - Genitourinary tumours, prostate
Resources:
Abstract
Slides
Webcast